In September 2018, the Centers for Medicare & Medicaid Services (CMS) sent an email announcing that it would no longer cover Auryxia®. Auryxia® is an FDA approved medicine that treats iron deficiency ...

Keryx’s Auryxia has so far struggled to get off the ground. But after winning its second FDA approval, the company’s now prepping for a launch that it thinks can take the drug to the next level.

At any point during the 16-week efficacy period, 52.1% (n=61/117) of the Auryxia treated group demonstrated hemoglobin levels of ≥1g/dL compared to 19.1% (n=22/115) of the placebo group. The Food and ...

Please provide your email address to receive an email when new articles are posted on . Keryx Biopharmaceuticals Inc. said it has started shipping Auryxia (ferric citrate) tablets to wholesalers in ...

Akebia Therapeutics, a small Cambridge, Mass.-based drugmaker, has filed a lawsuit against CMS, claiming Medicare’s denial to cover its anemia drug violates the law, according to STAT. Akebia’s only ...

(RTTNews) - Akebia Therapeutics, Inc. (AKBA) Thursday announced positive results from its Phase 4 collaborative study, IMPACT, which examined the effects of Auryxia or ferric citrate as the primary ...

NEW YORK, Nov. 17, 2014 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) (the "Company"), a biopharmaceutical company focused on bringing innovative therapies to market for patients ...

Please provide your email address to receive an email when new articles are posted on . The share price of dialysis drug maker Keryx Biopharmaceuticals went down almost 48% this week after the company ...

Keryx Biopharmaceuticals announced an interruption will occur in the supply of Auryxia (ferric citrate) tablets due to a production-related issue. Keryx Biopharmaceuticals announced an interruption ...

DUBLIN--(BUSINESS WIRE)--The "Drug Analysis: Auryxia" drug pipelines has been added to ResearchAndMarkets.com's offering. Auryxia (ferric citrate; Keryx Biopharmaceuticals/Japan Tobacco/Torii ...

Total revenues for Q4 2025 were $57.6 million, with Vafseo net product revenues at $6.2 million and Auryxia net product revenues at $48.1 million. Net loss in Q4 2025 was $12.2 million. Cash and cash ...

Akebia Therapeutics (NASDAQ:AKBA) stock fell ~22% on Thursday despite Q4 results beating estimates. Net loss narrowed to -$7.55M, compared to -$70.68M in Q4 2021. Total revenue declined -7.4% Y/Y to ...